Fusion Marketplace Changes Healthcare Traveler Experience

Fusion Marketplace is making openness as well as simplicity top priorities for traveling health care experts.

The traveler-first platform is changing the market by providing the health care specialist the power to have and manage their very own information as well as make choices about their occupation that they haven’t been able to in the past.

On Fusion Marketplace, health care experts will certainly have the ability to develop their health care tourist account, check out all healthcare staffing opportunities, and conveniently compare advantages, job pay, as well as examines throughout several jobs and companies.

“You can compare all the different pay bundles as well as jobs from numerous different firms in one spot, which is such a game-changer,” said Kylee Nelson, Registered Nurse. “I’m very upset this had not been around four years back when I began taking a trip, since that would certainly have made my life a lot easier.”

Fusion Marketplace introduced in February of 2021. Fusion Market believes what’s finest for Health care Travelers is finest for all staffing firms. The new online neighborhood is a one-stop buy tourist. It is a new curated career experience that obtains the uncertainty while providing the healthcare traveler with much better tools to improve the experience.

There are 3 companies currently on Fusion Marketplace, with a number of others signing up with quickly. Various other enhancements to the Industry are being included based upon the needs of traveling medical care professionals.

“We’ve finished studies and held panels with health care tourists so their voice is listened to, and also we constantly listen to how much transparency is valued,” said Sara Winters of Fusion Marketplace. “We wish to focus our energy in making certain Fusion Market benefits them as the sector adapts.”

To find out more regarding exactly how to sign up with Blend Industry and make the most out of your traveling health care occupation, most likely to fusionmarketplace.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”